Physician profile
Tomas J Chao
NPI 1316003577
$1,880,617.06
in general payments reported to CMS, 2019-2025
34 companies · $461K in 2025
The $461K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $207K · 2022: $286K · 2023: $417K · 2024: $510K · 2025: $461K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $978K · Travel and Lodging: $171K · Consulting Fee: $160K · Food and Beverage: $42K · Honoraria: $21K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $978,489.22 |
| Travel and Lodging | $170,930.63 |
| Consulting Fee | $159,806.78 |
| Food and Beverage | $41,668.28 |
| Honoraria | $21,200.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,319.10 |
| Education | $398.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $394,550.57 | 2021-2025 | Ebglyss, Olumiant, Taltz |
| Abbvie INC. | $271,930.02 | 2021-2025 | |
| Janssen Biotech, INC. | $232,919.76 | 2021-2025 | Tremfya |
| Ucb, INC. | $203,622.19 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $92,432.21 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $84,248.82 | 2022-2024 | Vtama |
| Incyte Corporation | $80,214.12 | 2022-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $77,420.26 | 2021-2025 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $72,319.33 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $69,037.31 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $66,692.25 | 2021-2025 | |
| Amgen INC. | $42,013.51 | 2021-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41,887.12 | 2021-2025 | Siliq, Cabtreo, Targretin |
| Sun Pharmaceutical Industries INC. | $29,874.36 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Organon LLC | $27,472.70 | 2024-2025 | Vtama, Nexplanon |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $26,362.68 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Galderma Laboratories, L.P. | $25,901.82 | 2021-2025 | Nemluvio, Aklief |
| Pfizer INC. | $11,682.26 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $6,186.94 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,810.04 | 2023-2024 | Spevigo |
| Botanix Sb INC | $4,401.32 | 2025 | Sofdra |
| Epi Health, LLC | $3,821.56 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $3,326.82 | 2025 | Zoryve |
| Mayne Pharma Commercial LLC | $2,876.64 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $2,149.90 | 2021-2025 | |
| Merz North America, INC. | $1,379.46 | 2021-2023 | |
| Journey Medical Corporation | $517.37 | 2021 | |
| Almirall LLC | $336.52 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $60.48 | 2024 | Ycanth |
| Eli Lilly and Company | $47.50 | 2024 | |
| Nabriva Therapeutics, Plc | $44.27 | 2021 | |
| Medtronic, INC. | $33.38 | 2023-2024 | Venaseal |
| Paratek Pharmaceuticals, INC. | $21.88 | 2022 | |
| Tempus Ai, INC | $21.69 | 2024 | Merlin Test |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomas Chao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.